Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | breast cancer 1, early onset | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Chlamydia trachomatis | DNA ligase | 0.0012 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | NAD-dependent DNA ligase, Lig | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | FHA domain containing protein, putative | 0.0012 | 0 | 0.5 |
Treponema pallidum | DNA ligase (lig) | 0.0012 | 0 | 0.5 |
Toxoplasma gondii | poly(ADP-ribose) polymerase catalytic domain-containing protein | 0.0012 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Mycobacterium ulcerans | NAD-dependent DNA ligase LigA | 0.0012 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE DNA LIGASE [NAD DEPENDENT] LIGA (POLYDEOXYRIBONUCLEOTIDE SYNTHASE [NAD+]) | 0.0012 | 0 | 0.5 |
Giardia lamblia | Replication factor C, subunit 1 | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0 | 0.5 |
Plasmodium vivax | replication factor C subunit 1, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Plasmodium falciparum | replication factor C subunit 1, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Toxoplasma gondii | ATPase, AAA family protein | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Trypanosoma brucei | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0 | 0.5 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | replication factor C large subunit, putative | 0.0012 | 0 | 0.5 |
Entamoeba histolytica | Activator 1 140 kDa subunit, putative | 0.0012 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.8184 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.